Federico Bussolino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4956262/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Role of TGFβ1 and WNT6 in FGF2 and BMP4-driven endothelial differentiation of murine embryonic stem cells. Angiogenesis, 2022, 25, 113-128.	7.2	3
2	Tumoral Neuroligin 1 Promotes Cancer–Nerve Interactions and Synergizes with the Glial Cell Line-Derived Neurotrophic Factor. Cells, 2022, 11, 280.	4.1	6
3	Oncostatin <scp>M</scp> is overexpressed in <scp>NASH</scp> â€related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis. Journal of Pathology, 2022, 257, 82-95.	4.5	12
4	Long Non-Coding RNA LINC02802 Regulates In Vitro Sprouting Angiogenesis by Sponging microRNA-486-5p. International Journal of Molecular Sciences, 2022, 23, 1653.	4.1	4
5	SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 75.	8.6	7
6	Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis. Digestive and Liver Disease, 2022, 54, S41.	0.9	0
7	TFEB controls integrin-mediated endothelial cell adhesion by the regulation of cholesterol metabolism. Angiogenesis, 2022, 25, 471-492.	7.2	10
8	Transcription factor EB controls both motogenic and mitogenic cell activities. FEBS Letters, 2022, 596, 1973-1980.	2.8	4
9	Multifaceted activities of transcription factor EB in cancer onset and progression. Molecular Oncology, 2021, 15, 327-346.	4.6	29
10	The Oncogene Transcription Factor EB Regulates Vascular Functions. Frontiers in Physiology, 2021, 12, 640061.	2.8	7
11	The role of redox system in metastasis formation. Angiogenesis, 2021, 24, 435-450.	7.2	5
12	Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma. Cancers, 2021, 13, 2332.	3.7	4
13	Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations. Cancers, 2021, 13, 2425.	3.7	7
14	miR-200c-3p Regulates Epitelial-to-Mesenchymal Transition in Epicardial Mesothelial Cells by Targeting Epicardial Follistatin-Related Protein 1. International Journal of Molecular Sciences, 2021, 22, 4971.	4.1	6
15	TFEB Signalling-Related MicroRNAs and Autophagy. Biomolecules, 2021, 11, 985.	4.0	11
16	Transmembrane Protein TMEM230, a Target of Glioblastoma Therapy. Frontiers in Cellular Neuroscience, 2021, 15, 703431.	3.7	1
17	Wnt/ILâ€1β/ILâ€8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5. International Journal of Cancer, 2020, 146, 192-207.	5.1	29
18	HIV Protease Inhibitors Block HPV16-Induced Murine Cervical Carcinoma and Promote Vessel Normalization in Association with MMP-9 Inhibition and TIMP-3 Induction. Molecular Cancer Therapeutics, 2020, 19, 2476-2489.	4.1	5

#	Article	IF	CITATIONS
19	Genetic perturbation of IFN-α transcriptional modulators in human endothelial cells uncovers pivotal regulators of angiogenesis. Computational and Structural Biotechnology Journal, 2020, 18, 3977-3986.	4.1	6
20	A regulatory microRNA network controls endothelial cell phenotypic switch during sprouting angiogenesis. ELife, 2020, 9, .	6.0	35
21	KRAS-Driven Metabolic Rewiring Reveals Novel Actionable Targets in Cancer. Frontiers in Oncology, 2019, 9, 848.	2.8	99
22	Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2019, 14, 1458-1471.	1.1	41
23	SerpinB3 Differently Up-Regulates Hypoxia Inducible Factors -1α and -2α in Hepatocellular Carcinoma: Mechanisms Revealing Novel Potential Therapeutic Targets. Cancers, 2019, 11, 1933.	3.7	22
24	Nanomedicine for Imaging and Therapy of Pancreatic Adenocarcinoma. Frontiers in Bioengineering and Biotechnology, 2019, 7, 307.	4.1	27
25	<scp>TFEB</scp> controls vascular development by regulating the proliferation of endothelial cells. EMBO Journal, 2019, 38, .	7.8	55
26	Targeted nanomedicines for applications in preclinical cancer models. Bulletin of Russian State Medical University, 2019, , 5-13.	0.2	0
27	PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations. Cell Death and Disease, 2018, 9, 45.	6.3	59
28	Bloch surface wave label-free and fluorescence platform for the detection of VEGF biomarker in biological matrices. Sensors and Actuators B: Chemical, 2018, 255, 2143-2150.	7.8	25
29	Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment. Oncolmmunology, 2018, 7, e1398874.	4.6	41
30	MRCKα is activated by caspase cleavage to assemble an apical actin ring for epithelial cell extrusion. Journal of Cell Biology, 2018, 217, 231-249.	5.2	27
31	Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis, 2018, 21, 425-532.	7.2	429
32	Modulation of Angiopoietin 2 release from endothelial cells and angiogenesis by the synaptic protein Neuroligin 2. Biochemical and Biophysical Research Communications, 2018, 501, 165-171.	2.1	5
33	Bloch surface wave enhanced biosensor for the direct detection of Angiopoietin-2 tumor biomarker in human plasma. Biomedical Optics Express, 2018, 9, 529.	2.9	19
34	Tumor progression: the neuronal input. Annals of Translational Medicine, 2018, 6, 89-89.	1.7	47
35	MicroRNA-mediated regulatory circuits: outlook and perspectives. Physical Biology, 2017, 14, 045001.	1.8	73
36	Bioengineered tumoral microtissues recapitulate desmoplastic reaction of pancreatic cancer. Acta Biomaterialia, 2017, 49, 152-166.	8.3	60

#	Article	IF	CITATIONS
37	Sema3F (Semaphorin 3F) Selectively Drives an Extraembryonic Proangiogenic Program. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1710-1721.	2.4	12
38	<scp>VEGF</scp> blockade enhances the antitumor effect of <scp> BRAF ^V </scp> ^{600E} inhibition. EMBO Molecular Medicine, 2017, 9, 219-237.	6.9	36
39	An Electrical Impedance-Based Method for Quantitative Real-Time Analysis of Semaphorin-Elicited Endothelial Cell Collapse. Methods in Molecular Biology, 2017, 1493, 195-207.	0.9	4
40	Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies. Frontiers in Cell and Developmental Biology, 2017, 5, 101.	3.7	65
41	BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer. Clinical Cancer Research, 2016, 22, 4923-4933.	7.0	50
42	Hydrogel-Terminated Photonic Crystal for Label-Free Detection of Angiopoietin-1. Journal of Lightwave Technology, 2016, 34, 3641-3645.	4.6	16
43	Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. ESMO Open, 2016, 1, e000118.	4.5	6
44	SPAD aptasensor for the detection of circulating protein biomarkers. Biosensors and Bioelectronics, 2015, 68, 500-507.	10.1	24
45	PDK1 regulates focal adhesion disassembly through modulation of αvβ3 integrin endocytosis. Journal of Cell Science, 2015, 128, 863-77.	2.0	16
46	Real-time monitoring of cell protrusion dynamics by impedance responses. Scientific Reports, 2015, 5, 10206.	3.3	28
47	The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination. Scientific Reports, 2015, 5, 9054.	3.3	56
48	The Neuronal Pentraxin-2 Pathway Is an Unrecognized Target in Human Neuroblastoma, Which Also Offers Prognostic Value in Patients. Cancer Research, 2015, 75, 4265-4271.	0.9	20
49	Three-Dimensional In Vitro Assay of Endothelial Cell Invasion and Capillary Tube Morphogenesis. Methods in Molecular Biology, 2015, 1214, 41-47.	0.9	6
50	Class 3 Semaphorin in Angiogenesis and Lymphangiogenesis. Chemical Immunology and Allergy, 2014, 99, 71-88.	1.7	15
51	PDK1-mediated activation of MRCKα regulates directional cell migration and lamellipodia retraction. Journal of Cell Biology, 2014, 206, 415-434.	5.2	43
52	Neuroligin 1 Induces Blood Vessel Maturation by Cooperating with the α6 Integrin. Journal of Biological Chemistry, 2014, 289, 19466-19476.	3.4	31
53	Neuroligin 1 induces blood vessel maturation by cooperating with the α6 integrin Journal of Biological Chemistry, 2014, 289, 25475.	3.4	0
54	Bloch Surface Waves on Dielectric Photonic Crystals for Biological Sensing. Lecture Notes in Electrical Engineering, 2014, , 107-111.	0.4	0

#	Article	IF	CITATIONS
55	Semaphorins in cardiovascular medicine. Trends in Molecular Medicine, 2014, 20, 589-598.	6.7	16
56	Angiopoietin-like 7, a novel pro-angiogenetic factor over-expressed in cancer. Angiogenesis, 2014, 17, 881-896.	7.2	55
57	Endothelial podosome rosettes regulate vascular branching in tumour angiogenesis. Nature Cell Biology, 2014, 16, 931-941.	10.3	107
58	Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings. Journal of Controlled Release, 2013, 170, 233-241.	9.9	41
59	A peptide from the extracellular region of the synaptic protein α Neurexin stimulates angiogenesis and the vascular specific tyrosine kinase Tie2. Biochemical and Biophysical Research Communications, 2013, 432, 574-579.	2.1	9
60	The V1/V2 loop of HIVâ€1 gp120 is necessary for Tat binding and consequent modulation of virus entry. FEBS Letters, 2013, 587, 2943-2951.	2.8	8
61	Class 3 semaphorins: physiological vascular normalizing agents for antiâ€cancer therapy. Journal of Internal Medicine, 2013, 273, 138-155.	6.0	37
62	Emerging lymphae for the fountain of life. EMBO Journal, 2013, 32, 609-611.	7.8	6
63	A Fluorescent One-Dimensional Photonic Crystal for Label-Free Biosensing Based on Bloch Surface Waves. Sensors, 2013, 13, 2011-2022.	3.8	56
64	Modeling human tumor angiogenesis in a three-dimensional culture system. Blood, 2013, 121, e129-e137.	1.4	64
65	Differential regulation of neurexin at glutamatergic and GABAergic synapses. Frontiers in Cellular Neuroscience, 2013, 7, 35.	3.7	17
66	The R-Ras/RIN2/Rab5 complex controls endothelial cell adhesion and morphogenesis via active integrin endocytosis and Rac signaling. Cell Research, 2012, 22, 1479-1501.	12.0	97
67	Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E353-9.	7.1	51
68	Liver X Receptor Activation Reduces Angiogenesis by Impairing Lipid Raft Localization and Signaling of Vascular Endothelial Growth Factor Receptor-2. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2280-2288.	2.4	61
69	Semaphorin 4A Exerts a Proangiogenic Effect by Enhancing Vascular Endothelial Growth Factor-A Expression in Macrophages. Journal of Immunology, 2012, 188, 4081-4092.	0.8	64
70	Neuropilin-1 Identifies a Subset of Bone Marrow Gr1â ^{~?} Monocytes That Can Induce Tumor Vessel Normalization and Inhibit Tumor Growth. Cancer Research, 2012, 72, 6371-6381.	0.9	51
71	Unraveling the influence of endothelial cell density on VEGF-A signaling. Blood, 2012, 119, 5599-5607.	1.4	30
72	The miR-126 regulates Angiopoietin-1 signaling and vessel maturation by targeting p85β. Biochimica Et Biophysica Acta - Molecular Cell Research, 2012, 1823, 1925-1935.	4.1	77

#	Article	IF	CITATIONS
73	A complex of α ₆ integrin and Eâ€cadherin drives liver metastasis of colorectal cancer cells through hepatic angiopoietinâ€like 6. EMBO Molecular Medicine, 2012, 4, 1156-1175.	6.9	44
74	IL-12-dependent innate immunity arrests endothelial cells in G0–G1 phase by a p21Cip1/Waf1-mediated mechanism. Angiogenesis, 2012, 15, 713-725.	7.2	5
75	The Synaptic Proteins β-Neurexin and Neuroligin Synergize With Extracellular Matrix-Binding Vascular Endothelial Growth Factor A During Zebrafish Vascular Development. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 1563-1572.	2.4	24
76	3-Phosphoinositide-Dependent Kinase 1 Controls Breast Tumor Growth in a Kinase-Dependent but Akt-Independent Manner. Neoplasia, 2012, 14, 719-IN19.	5.3	57
77	Targeted dual-color silica nanoparticles provide univocal identification of micrometastases in preclinical models of colorectal cancer. International Journal of Nanomedicine, 2012, 7, 4797.	6.7	31
78	SERS active Ag nanoparticles in mesoporous silicon: detection of organic molecules and peptide–antibody assays. Journal of Raman Spectroscopy, 2012, 43, 730-736.	2.5	70
79	Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. Journal of Clinical Investigation, 2012, 122, 1832-1848.	8.2	154
80	A transient kinetic study between signaling proteins: the case of the MEK–ERK interaction. Chemical Science, 2011, 2, 1804.	7.4	8
81	Ex vivo-expanded bone marrow CD34+ for acute myocardial infarction treatment: in vitro and in vivo studies. Cytotherapy, 2011, 13, 1140-1152.	0.7	8
82	Nervous vascular parallels: axon guidance and beyond. International Journal of Developmental Biology, 2011, 55, 439-445.	0.6	27
83	Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase. Blood, 2011, 117, 4658-4666.	1.4	64
84	Mature endothelium and neurons are simultaneously derived from embryonic stem cells by 2D <i>in vitro</i> culture system. Journal of Cellular and Molecular Medicine, 2011, 15, 2200-2215.	3.6	4
85	Simplification of a complex signal transduction model using invariants and flow equivalent servers. Theoretical Computer Science, 2011, 412, 6036-6057.	0.9	15
86	Neurexins and neuroligins: synapses look out of the nervous system. Cellular and Molecular Life Sciences, 2011, 68, 2655-2666.	5.4	51
87	Small GTPase Rab5 participates in chromosome congression and regulates localization of the centromere-associated protein CENP-F to kinetochores. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17337-17342.	7.1	50
88	Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. Journal of Controlled Release, 2010, 145, 66-73.	9.9	78
89	Characterization of the neuroligin gene family expression and evolution in zebrafish. Developmental Dynamics, 2010, 239, 688-702.	1.8	19
90	Development of microcantilever-based biosensor array to detect Angiopoietin-1, a marker of tumor angiogenesisa~†. Biosensors and Bioelectronics, 2010, 25, 1193-1198.	10.1	47

#	Article	IF	CITATIONS
91	Integration of microfluidic and cantilever technology for biosensing application in liquid environment. Biosensors and Bioelectronics, 2010, 26, 1565-1570.	10.1	58
92	Protein Kinase D1 Regulates VEGF-A-Induced αvβ3 Integrin Trafficking and Endothelial Cell Migration. Traffic, 2010, 11, 1107-1118.	2.7	35
93	Increased Expression of α6 Integrin in Endothelial Cells Unveils a Proangiogenic Role for Basement Membrane. Cancer Research, 2010, 70, 5759-5769.	0.9	60
94	Integrin signaling and lung cancer. Cell Adhesion and Migration, 2010, 4, 124-129.	2.7	47
95	Role of the microenvironment in the specification of endothelial progenitors derived from embryonic stem cells. Microvascular Research, 2010, 79, 178-183.	2.5	16
96	Microenvironment drives the endothelial or neural fate of differentiating embryonic stem cells coexpressing neuropilinâ€1 and Flkâ€1. FASEB Journal, 2009, 23, 68-78.	0.5	17
97	The synaptic proteins neurexins and neuroligins are widely expressed in the vascular system and contribute to its functions. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20782-20787.	7.1	55
98	Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. Journal of Clinical Investigation, 2009, 119, 3356-72.	8.2	167
99	Neuropilin-1/GIPC1 Signaling Regulates α5β1 Integrin Traffic and Function in Endothelial Cells. PLoS Biology, 2009, 7, e1000025.	5.6	246
100	Semaphorins and tumor angiogenesis. Angiogenesis, 2009, 12, 187-193.	7.2	46
101	Fluorescence anisotropy analysis of protein–antibody interaction. Dyes and Pigments, 2009, 83, 225-229.	3.7	18
102	A study of the interaction between fluorescein sodium salt and bovine serum albumin by steady-state fluorescence. Dyes and Pigments, 2009, 80, 307-313.	3.7	132
103	LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms. Atherosclerosis, 2009, 207, 38-44.	0.8	64
104	Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Molecular Cancer, 2009, 8, 118.	19.2	159
105	Angiogenesis: aÂbalancing act between integrin activation andÂinhibition?. European Cytokine Network, 2009, 20, 191-196.	2.0	9
106	On the Use of Stochastic Petri Nets in the Analysis of Signal Transduction Pathways for Angiogenesis Process. Lecture Notes in Computer Science, 2009, , 281-295.	1.3	14
107	VRG: A database of vascular dysfunctions related genes. Computers and Mathematics With Applications, 2008, 55, 1068-1073.	2.7	1
108	Diacylglycerol kinase-α phosphorylation by Src on Y335 is required for activation, membrane recruitment and Hgf-induced cell motility. Oncogene, 2008, 27, 942-956.	5.9	50

#	Article	IF	CITATIONS
109	Besides adhesion: new perspectives of integrin functions in angiogenesis. Cardiovascular Research, 2008, 78, 213-222.	3.8	55
110	Integrins team up with tyrosine kinase receptors and plexins to control angiogenesis. Current Opinion in Hematology, 2008, 15, 235-242.	2.5	25
111	A Simulation Environment for Directional Sensing as a Phase Separation Process. Science's STKE: Signal Transduction Knowledge Environment, 2007, 2007, pl1-pl1.	3.9	6
112	Essential role of PDK1 in regulating endothelial cell migration. Journal of Cell Biology, 2007, 176, 1035-1047.	5.2	75
113	Comparative Genome Analysis of the Neurexin Gene Family in Danio rerio: Insights into Their Functions and Evolution. Molecular Biology and Evolution, 2007, 24, 236-252.	8.9	38
114	Osteopontin Overexpression Inhibits in Vitro Re-endothelialization via Integrin Engagement. Journal of Biological Chemistry, 2007, 282, 19676-19684.	3.4	27
115	A new computational approach to analyze human protein complexes and predict novel protein interactions. Genome Biology, 2007, 8, R256.	9.6	8
116	Integrins: A flexible platform for endothelial vascular tyrosine kinase receptors. Autoimmunity Reviews, 2007, 7, 18-22.	5.8	17
117	Embryonic cleavage modeling as a computational approach to sphere packing problem. Journal of Theoretical Biology, 2007, 245, 77-82.	1.7	4
118	Integrins and angiogenesis: A sticky business. Experimental Cell Research, 2006, 312, 651-658.	2.6	186
119	Loss of inhibitory semaphorin 3A (SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma. Blood, 2006, 108, 1661-1667.	1.4	79
120	Small Molecule Approaches for Promoting Ischemic Tissue Vascularization. Circulation Research, 2006, 99, 231-233.	4.5	1
121	Type I Collagen Limits VEGFR-2 Signaling by a SHP2 Protein-Tyrosine Phosphatase–Dependent Mechanism 1. Circulation Research, 2006, 98, 45-54.	4.5	55
122	Semaphoring Vascular Morphogenesis. Endothelium: Journal of Endothelial Cell Research, 2006, 13, 81-91.	1.7	49
123	A Computational Model for Eukaryotic Directional Sensing. Lecture Notes in Computer Science, 2006, , 184-195.	1.3	0
124	Inhibition of vascular endothelial growth factor receptor 2–mediated endothelial cell activation by Axl tyrosine kinase receptor. Blood, 2005, 105, 1970-1976.	1.4	98
125	Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein. Blood, 2005, 105, 2802-2811.	1.4	44
126	Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood, 2005, 105, 4321-4329.	1.4	226

#	Article	IF	CITATIONS
127	Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood, 2005, 106, 3423-3431.	1.4	153
128	Gorham-Stout Syndrome: A Monocyte-Mediated Cytokine Propelled Disease. Journal of Bone and Mineral Research, 2005, 21, 207-218.	2.8	64
129	Stable interaction between α5β1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1. Journal of Cell Biology, 2005, 170, 993-1004.	5.2	162
130	Diffusion-limited phase separation in eukaryotic chemotaxis. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16927-16932.	7.1	85
131	Identification of CD36 molecular features required for its in vitro angiostatic activity. FASEB Journal, 2005, 19, 1713-1715.	0.5	73
132	A Review of Vasculogenesis Models. Journal of Theoretical Medicine, 2005, 6, 1-19.	0.5	64
133	Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clinical Cancer Research, 2005, 11, 490-7.	7.0	83
134	Vasculogenic potential of long term repopulating cord blood progenitors. FASEB Journal, 2004, 18, 1273-1275.	0.5	20
135	Human Immunodeficiency Virus Type 1 Tat Regulates Endothelial Cell Actin Cytoskeletal Dynamics through PAK1 Activation and Oxidant Production. Journal of Virology, 2004, 78, 779-789.	3.4	58
136	Adaptor ShcA Protein Binds Tyrosine Kinase Tie2 Receptor and Regulates Migration and Sprouting but Not Survival of Endothelial Cells. Journal of Biological Chemistry, 2004, 279, 13224-13233.	3.4	44
137	Common Cues in Vascular and Axon Guidance. Physiology, 2004, 19, 348-354.	3.1	39
138	Activation of diacylglycerol kinase Î \pm is required for VEGF-induced angiogenic signaling in vitro. Oncogene, 2004, 23, 4828-4838.	5.9	69
139	Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell, 2004, 5, 151-162.	16.8	132
140	CCL16 activates an angiogenic program in vascular endothelial cells. Blood, 2004, 103, 40-49.	1.4	85
141	Modeling the early stages of vascular network assembly. EMBO Journal, 2003, 22, 1771-1779.	7.8	280
142	Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. International Journal of Cancer, 2003, 103, 466-474.	5.1	182
143	Insulin-like growth factor binding protein-3 is overexpressed in endothelial cells of mouse breast tumor vessels. International Journal of Cancer, 2003, 103, 577-586.	5.1	26
144	Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature, 2003, 424, 391-397.	27.8	546

#	Article	IF	CITATIONS
145	Percolation, Morphogenesis, and Burgers Dynamics in Blood Vessels Formation. Physical Review Letters, 2003, 90, 118101.	7.8	222
146	IL-12 Regulates an Endothelial Cell-Lymphocyte Network: Effect on Metalloproteinase-9 Production. Journal of Immunology, 2003, 171, 3725-3733.	0.8	56
147	Temporal and Spatial Modulation of Rho GTPases during in Vitro Formation of Capillary Vascular Network. Journal of Biological Chemistry, 2003, 278, 50702-50713.	3.4	64
148	Tumor-host interaction mediates the regression of BK virus-induced vascular tumors in mice: involvement of transforming growth factor-Â1. Carcinogenesis, 2003, 24, 1435-1444.	2.8	8
149	Tie-2–dependent activation of RhoA and Rac1 participates in endothelial cell motility triggered by angiopoietin-1. Blood, 2003, 102, 2482-2490.	1.4	57
150	Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism. Cancer Research, 2003, 63, 1500-7.	0.9	58
151	Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. Journal of Cell Biology, 2002, 159, 1029-1037.	5.2	673
152	In vivoactivation of JAK2/STATâ€3 pathway during angiogenesis induced by GM SF. FASEB Journal, 2002, 16, 1-19.	0.5	126
153	Recombinant AAV vector encoding human VEGF165 enhances wound healing. Gene Therapy, 2002, 9, 777-785.	4.5	123
154	HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nature Medicine, 2002, 8, 225-232.	30.7	299
155	Involvement of a serine protease, but not of neutrophil elastase, in tumor necrosis factor-induced lethal hepatitis and induction of platelet-activating factor. Journal of Hepatology, 2001, 35, 490-497.	3.7	7
156	Interactions between endothelial cells and HIV-1. International Journal of Biochemistry and Cell Biology, 2001, 33, 371-390.	2.8	59
157	Tat-induced platelet-activating factor synthesis contributes to the angiogenic effect of HIV-1 Tat. European Journal of Immunology, 2001, 31, 376-383.	2.9	23
158	Dynamic modules and heterogeneity of function: a lesson from tyrosine kinase receptors in endothelial cells. EMBO Reports, 2001, 2, 763-767.	4.5	25
159	IL-12 Inhibition of Endothelial Cell Functions and Angiogenesis Depends on Lymphocyte-Endothelial Cell Cross-Talk. Journal of Immunology, 2001, 166, 3890-3899.	0.8	157
160	Cytoadherence ofPlasmodium falciparum-Infected Erythrocytes Is Mediated by a Redox-Dependent Conformational Fraction of CD36. Journal of Immunology, 2001, 167, 6510-6517.	0.8	19
161	Expression of Angiopoietin-1 in Human Glioblastomas Regulates Tumor-Induced Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 536-541.	2.4	50
162	HIV-1 Tat Protein Stimulates In Vivo Vascular Permeability and Lymphomononuclear Cell Recruitment. Journal of Immunology, 2001, 166, 1380-1388.	0.8	58

#	Article	IF	CITATIONS
163	Cu(II) and Zn(II) complexes with hyaluronic acid and its sulphated derivative. Journal of Inorganic Biochemistry, 2000, 81, 229-237.	3.5	27
164	Human endothelial cells expressing polyoma middle T induce tumors. Oncogene, 2000, 19, 3632-3641.	5.9	24
165	Identification of Specific Molecular Structures of Human Immunodeficiency Virus Type 1 Tat Relevant for Its Biological Effects on Vascular Endothelial Cells. Journal of Virology, 2000, 74, 344-353.	3.4	62
166	Human Immunodeficiency Virus Transactivator Protein (Tat) Stimulates Chemotaxis, Calcium Mobilization, and Activation of Human Polymorphonuclear Leukocytes: Implications for Tatâ€Mediated Pathogenesis. Journal of Infectious Diseases, 2000, 182, 1643-1651.	4.0	70
167	Aberrantly glycosylated IgA molecules downregulate the synthesis and secretion of vascular endothelial growth factor in human mesangial cells. American Journal of Kidney Diseases, 2000, 36, 1242-1252.	1.9	45
168	Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma. Blood, 1999, 93, 3064-3073.	1.4	537
169	c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 9671-9676.	7.1	240
170	Vascular Endothelial Growth Factor-C Stimulates the Migration and Proliferation of Kaposi's Sarcoma Cells. Journal of Biological Chemistry, 1999, 274, 27617-27622.	3.4	86
171	Role of αvβ3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO Journal, 1999, 18, 882-892.	7.8	562
172	Platelet activating factor is elevated in cerebral spinal fluid and plasma of patients with relapsing–remitting multiple sclerosis. Journal of Neuroimmunology, 1999, 94, 212-221.	2.3	71
173	Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma. Blood, 1999, 93, 3064-3073.	1.4	119
174	Human Immunodeficiency Virus-1 (HIV-1)-Tat Protein Promotes Migration of Acquired Immunodeficiency Syndrome–Related Lymphoma Cells and Enhances Their Adhesion to Endothelial Cells. Blood, 1999, 94, 1747-1754.	1.4	25
175	Human Immunodeficiency Virus-1 (HIV-1)-Tat Protein Promotes Migration of Acquired Immunodeficiency Syndrome–Related Lymphoma Cells and Enhances Their Adhesion to Endothelial Cells. Blood, 1999, 94, 1747-1754.	1.4	5
176	Role of Inflammatory Mediators in Angiogenesis. , 1999, , 37-50.		0
177	Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis. International Journal of Clinical and Laboratory Research, 1998, 28, 55-68.	1.0	85
178	Tumor Necrosis Factor-α Regulates Expression of Vascular Endothelial Growth Factor Receptor-2 and of Its Co-receptor Neuropilin-1 in Human Vascular Endothelial Cells. Journal of Biological Chemistry, 1998, 273, 22128-22135.	3.4	232
179	Role of IL-6 and Its Soluble Receptor in Induction of Chemokines and Leukocyte Recruitment. Immunity, 1997, 6, 315-325.	14.3	1,022
180	Human monocyte-derived and CD34+cell-derived dendritic cells express functional receptors for platelet activating factor. FEBS Letters, 1997, 418, 98-100.	2.8	49

#	Article	IF	CITATIONS
181	Activation of JAK2 in Human Vascular Endothelial Cells by Granulocyte-Macrophage Colony-Stimulating Factor. Blood, 1997, 89, 863-872.	1.4	42
182	Tat–Human Immunodeficiency Virus-1 Induces Human Monocyte Chemotaxis by Activation of Vascular Endothelial Growth Factor Receptor-1. Blood, 1997, 90, 1365-1372.	1.4	103
183	Molecular mechanisms of blood vessel formation. Trends in Biochemical Sciences, 1997, 22, 251-256.	7.5	410
184	Cytokine regulation of endothelial cell function: from molecular level to the bedside. Trends in Immunology, 1997, 18, 231-240.	7.5	370
185	Tat–Human Immunodeficiency Virus-1 Induces Human Monocyte Chemotaxis by Activation of Vascular Endothelial Growth Factor Receptor-1. Blood, 1997, 90, 1365-1372.	1.4	3
186	Anti-tumor activity of cytokines against opportunistic vascular tumors in mice. , 1996, 65, 700-708.		11
187	Microvessel count is predictive of patients' survival in laryngeal squamous-cell carcinoma. , 1996, 69, 426-427.		3
188	The angiogenesis induced by HIV–1 Tat protein is mediated by the Flk–1/KDR receptor on vascular endothelial cells. Nature Medicine, 1996, 2, 1371-1375.	30.7	363
189	Platelet-Activating Factor Produced by Endothelial Cells. A Molecule with Autocrine and Paracrine Properties. FEBS Journal, 1995, 229, 327-337.	0.2	16
190	Platelet-activating factor production by human fetal microglia. Molecular and Chemical Neuropathology, 1995, 24, 95-106.	1.0	35
191	A possible role for nitric oxide in modulating the functional cyclosporine toxicity by arginine. Kidney International, 1995, 47, 1507-1514.	5.2	55
192	In Vivo Activation of <i>met</i> Tyrosine Kinase by Heterodimeric Hepatocyte Growth Factor Molecule Promotes Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1857-1865.	2.4	89
193	Erythrocyte stages of Plasmodium falciparum exhibit a high nitric oxide synthase (NOS) activity and release an NOS-inducing soluble factor Journal of Experimental Medicine, 1995, 182, 677-688.	8.5	96
194	Middle T antigen-transformed endothelial cells exhibit an increased activity of nitric oxide synthase Journal of Experimental Medicine, 1995, 181, 9-19.	8.5	38
195	Multiple roles of platelet-activating factor in the nervous system. Neurochemistry International, 1995, 26, 425-433.	3.8	11
196	Platelet-Activating Factor Produced by Endothelial Cells. A Molecule with Autocrine and Paracrine Properties. FEBS Journal, 1995, 229, 327-337.	0.2	67
197	Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis Journal of Clinical Investigation, 1995, 96, 940-952.	8.2	98

Platelet-activating factor produced by endothelial cells. , 1995, , 109-119.

0

#	Article	IF	CITATIONS
199	Protective Effects of L-659,989, a Platelet-Activating Factor Receptor Antagonist, in Myocardial Ischemia and Reperfusion in Rats. Journal of Cardiovascular Pharmacology, 1994, 23, 7-12.	1.9	14
200	Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis Journal of Experimental Medicine, 1994, 180, 377-382.	8.5	144
201	Involvement of a serine protease in the synthesis of platelet-activating factor by endothelial cells stimulated by tumor necrosis factor-α or interleukin-1α. European Journal of Immunology, 1994, 24, 3131-3139.	2.9	30
202	Synergism Between Platelet Activating Factor and C-C Chemokines for Arachidonate Release in Human Monocytes. Biochemical and Biophysical Research Communications, 1994, 199, 761-766.	2.1	40
203	Proliferative and migratory responses of murine microvascular endothelial cells to granulocyte-colony-stimulating factor. Journal of Cellular Physiology, 1993, 155, 89-95.	4.1	66
204	Recent developments in the cell biology of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor: activities on endothelial cells. International Journal of Clinical and Laboratory Research, 1993, 23, 8-12.	1.0	36
205	Differential Expression of the Common β and Specific α Chains of the Receptors for GM-CSF, IL-3, and IL-5 in Endothelial Cells. Experimental Cell Research, 1993, 206, 311-317.	2.6	63
206	Streptokinase induces intravascular release of platelet-activating factor in patients with acute myocardial infarction and stimulates its synthesis by cultured human endothelial cells Circulation, 1993, 88, 1476-1483.	1.6	44
207	Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth Journal of Cell Biology, 1992, 119, 629-641.	5.2	1,282
208	Nitrovasodilators inhibit thrombin-induced platelet-activating factor synthesis in human endothelial cells. Biochemical Pharmacology, 1992, 44, 223-229.	4.4	44
209	Platelet activating factor interaction with tumor necrosis factor and myocardial depressant factor in splanchnic artery occlusion shock. European Journal of Pharmacology, 1992, 222, 13-19.	3.5	34
210	Cytokine regulation of endothelial cell function. FASEB Journal, 1992, 6, 2591-2599.	0.5	643
211	Protein kinase C and cyclic AMP modulate thrombin-induced platelet-activating factor synthesis in human endothelial cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 1991, 1093, 55-64.	4.1	40
212	Tumor Necrosis Factor Alters Cytoskeletal Organization and Barrier Function of Endothelial Cells. International Archives of Allergy and Immunology, 1991, 96, 84-91.	2.1	50
213	Dictyostelium cells produce platelet-activating factor in response to cAMP. FEBS Journal, 1991, 196, 609-615.	0.2	21
214	The molecular action of tumor necrosis factorâ€Î±. FEBS Journal, 1991, 202, 3-14.	0.2	240
215	GM-CSF and phorbol esters modulate GM-CSF receptor expression by independent mechanisms. Journal of Cellular Physiology, 1991, 148, 24-34.	4.1	9
216	Na+/H+ antiporter has different properties in human B lymphocytes according to CD5 expression and malignant phenotype. European Journal of Immunology, 1991, 21, 583-588.	2.9	10

#	Article	IF	CITATIONS
217	Role of Platelet Activating Factor in the Adhesion Process of Polymorphonuclear Neutrophils to Endothelial Cells. Advances in Experimental Medicine and Biology, 1991, 297, 55-64.	1.6	6
218	In vitro and in vivo activation of endothelial cells by colony-stimulating factors Journal of Clinical Investigation, 1991, 87, 986-995.	8.2	281
219	Release of Platelet-Activating Factor in Systemic Lupus erythematosus. International Archives of Allergy and Immunology, 1990, 91, 244-256.	2.1	72
220	Tumor necrosis factor induces contraction of mesangial cells and alters their cytoskeletons. Kidney International, 1990, 38, 795-802.	5.2	40
221	Effect of leukocyte stimulation on rabbit immune complex glomerulonephritis. Kidney International, 1990, 38, 1047-1055.	5.2	16
222	An antiâ€inflammatory protein secreted from the rat seminal vesicle epithelium inhibits the synthesis of plateletâ€activating factor and the release of arachidonic acid and prostacyclin. FEBS Journal, 1990, 192, 481-485.	0.2	21
223	In vivo priming of human normal neutrophils by granulocyte-macrophage colony stimulating factor: effect on the production of platelet activating factor. British Journal of Haematology, 1990, 75, 333-339.	2.5	14
224	Role of Na+/H+ exchange in the granulocyte-macrophage colony-stimulating factor-dependent growth of a leukemic cell line. Journal of Cellular Physiology, 1990, 143, 133-139.	4.1	8
225	Evidence for a role of the Na+/H+ exchanger in the colony-stimulating-factor-induced ornithine decarboxylase activity and proliferation of the human cell line M-07e. Journal of Cellular Physiology, 1990, 145, 147-154.	4.1	8
226	Acetylcholine-induced production of platelet-activating factor by human fetal brain cells in culture. Journal of Neuroscience Research, 1990, 27, 706-711.	2.9	77
227	Antiinflammatory peptides (antiflammins) inhibit synthesis of platelet-activating factor, neutrophil aggregation and chemotaxis, and intradermal inflammatory reactions Journal of Experimental Medicine, 1990, 171, 913-927.	8.5	82
228	Role of Cytokines and Platelet-Activating Factor in Microvascular Immune Injury. International Archives of Allergy and Immunology, 1989, 88, 88-100.	2.1	99
229	Tumor necrosis factor stimulates human neutrophils to release leukotriene B4 and platelet-activating factor. Induction of phospholipase A2 and acetyl-CoA:1-alkyl-sn-glycero-3-phosphocholine O2-acetyltransferase activity and inhibition by antiproteinase. FEBS Journal, 1989, 182, 661-666.	0.2	60
230	Granulocyte- and granulocyte– macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature, 1989, 337, 471-473.	27.8	640
231	Is there a case for PAF antagonists in the treatment of ischemie states?. Trends in Pharmacological Sciences, 1989, 10, 23-30.	8.7	129
232	Acetylcholine and Dopamine Promote the Production of Platelet Activating Factor in Immature Cells of Chick Embryonic Retina. Journal of Neurochemistry, 1988, 51, 1755-1759.	3.9	51
233	Naturally occurring anti-band-3 antibodies and complement together mediate phagocytosis of oxidatively stressed human erythrocytes Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 7368-7372.	7.1	216
234	Intravascular release of platelet activating factor in children with sepsis. Thrombosis Research, 1987, 48, 619-620.	1.7	49

#	Article	IF	CITATIONS
235	Endothelial cells and inflammation: The role of PAF, monokines and circulating cells. Prostaglandins, 1987, 34, 172.	1.2	0
236	FAP activates rat macrophages and enhances complement-mediateed phagocytes. Prostaglandins, 1987, 34, 174.	1.2	0
237	Unbalance between production and catabolism of platelet-activating factor (PAF) in human pathology. Studies of PAF acetylhydrolase (AH) in systemic lupus erythematosus (SLE). Prostaglandins, 1987, 34, 190.	1.2	1
238	Measurement of phagocytosis utilizing [14C]cyanate-labelled human red cells and monocytes. British Journal of Haematology, 1987, 66, 271-275.	2.5	25
239	Platelet-Activating Factor – A Powerful Lipid Autacoid Possibly Involved in Microangiopathy. Acta Haematologica, 1986, 75, 129-140.	1.4	31
240	Interleukin 1 stimulates platelet activating factor production in cultured human endothelial cells. Pharmacological Research Communications, 1986, 18, 133-137.	0.2	85
241	Platelet-activating factor phosphatidate, but not platelet-activating factor, is a powerful calcium ionophore in the human red cell. Cell Calcium, 1984, 5, 463-473.	2.4	8
242	Specific binding of 1-[3H]-O-alkyl-2-acetyl-sn-glyceryl-3-phosphoryl choline (platelet-activating factor,) Tj ETQq0 (0 0 ₇ gBT /C	Overlock 107 14
243	In vitro spasmogenic effect on rabbit lung tissue of 1-O-octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet-activating factor): Specific desensitization afterin vivo infusion. Agents and Actions, 1983, 13, 507-509.	0.7	3
244	Platelet-activating factor-mediated contraction of rabbit lung strips: Pharmacologic modulation. Immunopharmacology, 1983, 6, 87-96.	2.0	23
245	Neutropenia induced by platelet-activating factor (PAF-acether) released from neutrophils: The inhibitory effect of prostacyclin (PGI2). Agents and Actions, 1981, 11, 550-553.	0.7	29

246Effect of prostacyclin on platelet-activating factor induced rabbit platelet aggregation.1.224247VEGF-Mediated Signal Transduction in Tumor Angiogenesis. , 0, , .3